Hematologic Oncology

The FDA has accepted a biologics license application for glofitamab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Max S. Topp, MD, highlights the rationale for studying bispecific antibodies in newly diagnosed diffuse large B-cell lymphoma, how the safety profile of glofitamab plus R-CHOP contributes to its potential for outpatient administration, and where future directions with this research may lead.

The past decade has been a time of great progress in the research of Waldenström macroglobulinemia and the care of patients with the rare form of non-Hodgkin lymphoma.

A teenage injury cost him a career among the stars, so John F. DiPersio, MD, PhD, became a star hematologist/oncologist instead.

Japan’s Ministry of Health, Labor and Welfare has approved axicabtagene ciloleucel for the initial treatment of patients with relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

The FDA has approved mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

Brian A Jonas, MD, reviews the results of the phase 1 study evaluating the use of uproleselan in combination with azacitidine and venetoclax in patients that are older or unfit for treatment naïve acute myeloid leukemia (AML).

Overall survival is a critically relevant end point in randomized oncology clinical trials, but its interpretation is often not as straightforward as some may wish to acknowledge.

Harry Erba, MD, PhD shares an update from the recent ASH 2022 Annual Meeting on a phase 1/2 trial of the menin-KMT2A (MLL) Inhibitor ziftomenib in patients with relapsed or refractory acute myeloid leukemia.

Obecabtagene autoleucel elicited an overall remission rate of 70% in 50 efficacy-evaluable adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia, meeting the primary end point of the phase 2 FELIX trial.

Glofitamab, an investigational CD20xCD3 T-cell engaging bispecific antibody, demonstrated promising results in patients with relapsed/refractory diffuse large B-cell lymphoma who received at least 2 prior lines of therapy.

Tapan M. Kadia, MD evaluates the use of uproleselan, an E-selectin antagonist, in combination with LDAC and Cladribine in patients with treated secondary acute myeloid leukemia.

Alexander E. Perl, MD, MS, discusses the implications of the updated ELN guidelines, how genetic testing guides treatment in this disease, and ongoing research investigating novel AML targets such as NPM1 mutations or KMT2A translocations.

Joshua Brody, MD, discusses unmet needs in patient subgroups within Hodgkin lymphoma, recent advancements in the use of antibody-drug conjugates such as brentuximab vedotin and anti–PD-1 therapies in earlier lines of therapy, and future avenues for expanding the use of immunotherapy in this tumor type.

Dr Leif Stenke reviews data on XS004 in patients with chronic myeloid leukemia (CML) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.